Prefer to watch?
Not a line, a curve.
This page is a 9-minute read. The video explains why recovery arrives in stages: the early lift, the slower build, and the real signal that shows up months later. Keep scrolling for the full version.
Response isn't linear, and most of it isn't immediate.
The most common misconception about an MSC infusion is that nothing happens for weeks. That isn't the curve, but the timing is genuinely patient-specific. After a systemic IV, most patients report an early lift in sleep and energy within the first few weeks: some feel it in week one, others not until week two, three, or four, and a few build more gradually still. A small subset feel a mild flu-like reaction 24 to 72 hours after the infusion (a real side effect, not the dominant story). From there the response continues to build, with the genuine clinical signal (pain, function, validated scores) usually arriving between month two and month four and the bulk of the early benefit landing in the two-to-five-month range, then continuing to build for many patients through the first year and beyond. A direct joint, tendon, or spine injection runs a different early course (covered just below). This page maps both shapes.
What follows is the median patient. Your specific indication, baseline severity, and biology will shift the timing, but the shape (early lift, continued build, real signal, durable gains that often keep climbing) is remarkably consistent.
Early lift
Sleep often improves first; energy follows. Real, if subtle.
Continued build
Sleep and energy keep improving. Tissue work, mostly invisible, is underway.
First real signal
Validated outcome scores (pain, function) typically inflect here.
Still building
Gains hold, and for many keep climbing through the first year and beyond.
IV and direct injection recover differently.
The curve on this page is drawn for the systemic IV, where the first thing most patients notice is better sleep and steadier energy. A direct injection into a joint, tendon, ligament, or the spine starts the opposite way. The needle deliberately creates a small amount of inflammation in the tissue, so the first few days usually bring soreness at the treated site, not relief. That soreness is the mechanism working, not a setback. The meaningful signal then arrives on a slower clock than the IV, and it varies by site: hip, knee, shoulder, hands, and feet tend to move first, while the spine is the slowest region and the most likely to need a second session.
The two routes are not an either/or. Almost every injection patient also receives the IV, because the medical team treats the systemic dose as the foundation the local work builds on. If that describes you, expect both stories at once: the IV's early lift in sleep and energy, and the injection site's soreness, then build, on its own timeline. The dedicated timelines go deeper: joint injection, spine, and IV durability.
What you can do afterward also splits by site. A spine or disc injection is usually the lighter lift on activity: most patients have local soreness for about a week and are then cleared to return to normal activity. A peripheral joint injection (knee, hip, shoulder, hands, feet) asks more of you up front. The treated joint needs to be protected, so plan on staying off it with very limited activity for the first seven to ten days, then a slow, graded build over the next two to four weeks and again at six to eight weeks. Loading the joint too early works against the repair you came for.
The five-phase recovery curve.
Below is the canonical shape of a clinical response to a single allogeneic MSC infusion, plotted against a generic outcome score (higher is better). Note the early lift inside the first week, the continued build through month two, the inflection between months two and four, the durable response that consolidates by month six, and the gentler climb that continues for many patients through the first year and beyond. This is not a marketing chart; it's the integrated shape of what the literature and what we see in our own follow-up data both produce.
The shape matters as much as any single point on it. The early lift, whenever it arrives in those first weeks, is real but small; patients who expect that early window to fix the whole problem are reading the curve wrong. The validated improvement (pain, function, scores) is on a slower clock. Knowing the curve in advance is the difference between staying the course and panicking in month two.
The early lift is not the whole response. The slower build is not a failure. The curve is the curve, and knowing its shape is half the recovery.
Five phases, concretely.
The phases below correspond directly to the five marked points on the curve. Each is described by what most patients feel, what is normal, what would be a flag, and what to do during the window.
The early lift
Sleep often improves first. Energy follows, usually within the first few weeks.
Most patients report a real, if subtle, lift in the first few weeks after a systemic IV, though exactly when varies: some feel it in week one, others not until week three or four. Sleep quality typically improves first (deeper sleep, fewer wake-ups), and daytime energy follows. A smaller subset feels a mild flu-like reaction in the first 24 to 72 hours (a documented side effect, not the dominant story). Patients who also had a direct injection run a different early window: expect soreness at the injection site for the first several days as the inflammation does its work, not immediate relief. That is part of the mechanism, not a complication.
What to do. Hydrate. Protect the new sleep window. Light walking is fine and helpful. Avoid intense exercise and any anti-inflammatory medication other than acetaminophen for the first week; NSAIDs blunt exactly the signaling the cells need.
The build
Sleep and energy keep improving. The validated scores haven't moved yet.
The early-lift gains continue and deepen: better sleep, more daytime energy, often a quieter baseline of inflammation that patients notice in small ways (fewer aches climbing stairs, a clearer head in the afternoon). What is not happening yet is the big validated change in pain or function scores; that is on a slower clock. The cellular signaling work is happening at a tissue level you don't have a window into. The first measurable changes on imaging or labs typically appear at the end of this window, not the middle.
What to do. Resume normal activity. Begin or restart physical therapy if indicated. Do not get re-treated by another clinic; this is the most common point at which patients seeking a faster validated signal end up booking a second program before the first has produced its actual response.
The signal
The first real change in validated scores. Subtle, then unambiguous.
For most indications, the first genuinely meaningful improvement on validated outcome scores appears between weeks 8 and 16. Orthopedic patients notice that the joint they were guarding has stopped objecting to ordinary use. Autoimmune patients see flare frequency or severity drop. Pain scores fall by clinically meaningful amounts on validated instruments. The sleep and energy gains from the early lift are still there; what's new is the pain and function change.
What to do. This is when we record the primary outcome score (month-3 validated assessment). Keep a brief daily symptom journal; the contrast between weeks 8 and 14 is often more telling than any single day's snapshot.
The durable response
Gains consolidate. This is your durable response window.
The trajectory settles at a new, higher level and holds. Outcome scores stabilize; imaging changes (where applicable) hold; the activities you've added back stay added back. For many patients the curve does more than hold: gains keep accruing past month six, more gradually than the early climb but in the same direction. The early surge is over; the improvement is not.
What to do. Month-6 validated assessment. Discuss durability and any re-treatment conversation with your physician. Some patients elect a maintenance infusion in the 9–18 month window; the timing is dictated by the curve, not the calendar.
Continued gains
The arc does not stop at six months. For many patients, it keeps climbing.
Improvement commonly continues past the first half-year: a steadier joint at month nine, fewer autoimmune flares at month twelve, function still inching up a year out. The pace is slower than the early build, but the direction holds. For neurodegenerative, autoimmune, and other complex cases this is where stacked treatment matters most, because each round builds on the last. We are not erasing the diagnosis. We are moving your response, and that work can run for years.
What to do. Keep the annual assessment on the calendar. Talk with your physician about whether a maintenance or stacked infusion fits your curve. The relationship does not end at month twelve.
The symptom intensity matrix.
A reference for the people supporting you. Dots scale from open (none) to filled (significant). This matrix reflects the systemic IV course; a direct-injection patient typically sees the soreness row run higher in the first weeks and the gain rows begin later. If your real experience is one column to the right of the matrix in either direction, that's still within range. If it is two columns out, call us. That is what the contact line is for.
| Symptom | Wk 1 | Wk 2 | Mo 1 | Mo 2 | Mo 3 | Mo 4–12+ |
|---|---|---|---|---|---|---|
| Sleep quality (gain) | ||||||
| Daytime energy (gain) | ||||||
| Soreness in treated area | ||||||
| Functional improvement | ||||||
| Pain reduction (chronic) |
What is not normal.
The early lift in week 1 is expected. The slower build in pain and function scores through month two is expected. The signs below are not. If you see any of them, contact your physician directly. The after-hours line goes to a real person, not a queue.
Six symptoms that are not part of the curve.
Temperature over 38.5°C (101.3°F) at any point. Mild low-grade temperature in week one is normal; a true fever is not.
New or worsening dyspnea, especially within the first 72 hours. Call immediately and seek local emergency care if severe.
Any chest pain in the post-infusion window. Same protocol as any chest pain anywhere, emergency care first, then us.
Expanding redness, warmth, or discharge at the infusion site past day three. Usually treatable, but needs evaluation.
A continued, escalating worsening into month two (not the slower validated-score build, but real decline) warrants a call. Rare, but real.
Numbness, weakness, vision changes, or confusion at any point. Almost certainly unrelated, but worth ruling in/out.
Three clarifications.
What the curve isn't.
- It's not a guarantee. A subset of treated patients do not produce a clinically meaningful response on validated scores at month 3. The curve above is the median, not the floor.
- It's not indication-specific. Knee OA, autoimmune flares, and post-COVID recovery all roughly follow this shape, but the magnitude and exact week of inflection vary. Your physician's pre-treatment estimate is more specific than this generic curve.
- It's not a one-way ratchet. The curve does not climb forever: for many patients it keeps improving gradually through the first year and then holds, while a subset see a partial regression past month 9, which is what drives the maintenance-infusion conversation.
- It's not one timeline for everyone. This curve is drawn for the systemic IV. A direct joint or spine injection starts with soreness rather than lift and signals on a slower, site-dependent clock (the spine slowest of all), and most injection patients run that course alongside the IV, not instead of it.
Lift, build, signal, durable, still climbing. That's the shape.
The first few weeks bring an early lift in sleep and energy for most IV patients, though the exact timing varies from person to person. The build continues from there, the first real signal on validated pain and function scores arrives between months 2 and 4, and the bulk of the early benefit lands in the two-to-five-month range. From there the response holds, and for many patients it keeps climbing through the first year and beyond. Direct-injection patients start with soreness instead and respond on a slower, site-dependent clock, with the spine slowest. Knowing your own curve in advance is the single biggest thing that distinguishes patients who get the response from patients who panic in the middle of it.